Leukemia - Acute
Recurrent genetic abnormalities
Myeloid neoplasms due to topoisomerase II inhibitors

Author: Daniela Mihova, M.D. (see Authors page)

Revised: 30 March 2018, last major update February 2013

Copyright: (c) 2001-2018, PathologyOutlines.com, Inc.

PubMed Search: Myeloid neoplasms [title] due to topoisomerase II inhibitors

Related Topics: Therapy related myeloid neoplasms

Page views in 2018: 10
Page views in 2019 to date: 4
Cite this page: Mihova, D. Myeloid neoplasms due to topoisomerase II inhibitors. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/leukemiaamltherapyrelatedtopinhib.html. Accessed November 14th, 2019.
Definition / general
  • Topoisomerase II inhibitors: actimomycin, amsacrine, doxorubicin, etoposide, mitaxantrine, teniposide
  • Abrupt onset < 1 to 3 years after initiation of etoposide or teniposide with doxorubicin
  • Presents as acute monocytic or myelomonocytic leukemia
Prognostic factors
  • Poor prognosis; worse than de novo AML counterpart
  • Better if have recurrent genetic abnormalities; better than t-MDS
Molecular / cytogenetics description
  • Usually 11q23 and 21q22 abnormalities
  • Also t(15;17), inv(16), t(16;16) and (9;11)
Back to top